
Browsing restrictions can be lifted for a fee.
5.39%
Daxor corporation
-1.10%
Avg of Sector
-0.49%
S&P500
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Daxor corporation (DXR) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DXR's short-term business performance and financial health. For the latest updates on DXR's earnings releases, visit this page regularly.
According to historical valuation range analysis, Daxor corporation (DXR)'s current price-to-earnings (P/E) ratio is 1.96, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, Daxor corporation (DXR) reported an Operating Profit of 9.54M with an Operating Margin of 7,237.85% this period, representing a growth of 332.72% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Daxor corporation (DXR) announced revenue of 131.85K, with a Year-Over-Year growth rate of -81.04%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
In the latest report, Daxor corporation (DXR) did not achieve the “three margins increasing” benchmark, with a gross margin of -79.36%%, operating margin of 7,237.85%%, and net margin of 7,235.32%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess DXR's profit trajectory and future growth potential.
According to the past four quarterly reports, Daxor corporation (DXR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.89. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Daxor corporation (DXR)'s Free Cash Flow (FCF) for the period is -297.47K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 40.75% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Daxor corporation (DXR) has a Price-To-Earnings (PE) ratio of 1.96 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.